H.H. Sedlacek

871 total citations
7 papers, 737 citations indexed

About

H.H. Sedlacek is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, H.H. Sedlacek has authored 7 papers receiving a total of 737 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Oncology and 1 paper in Pharmacology. Recurrent topics in H.H. Sedlacek's work include Ubiquitin and proteasome pathways (2 papers), Cancer Treatment and Pharmacology (2 papers) and Angiogenesis and VEGF in Cancer (1 paper). H.H. Sedlacek is often cited by papers focused on Ubiquitin and proteasome pathways (2 papers), Cancer Treatment and Pharmacology (2 papers) and Angiogenesis and VEGF in Cancer (1 paper). H.H. Sedlacek collaborates with scholars based in Austria, Germany and United States. H.H. Sedlacek's co-authors include Edward A. Sausville, Adrian M. Senderowicz, Jörg Czech, Klaus Bosslet, Gurleen Kaur, Michael D. Losiewicz, Brett L. Carlson, Ramachandra Naik, Alexis D. Smith and Peter J. Worland and has published in prestigious journals such as International Journal of Cancer, Life Sciences and Critical Reviews in Oncology/Hematology.

In The Last Decade

H.H. Sedlacek

6 papers receiving 704 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
H.H. Sedlacek Austria	6	419	393	153	110	87	7	737
Banibrata Sen United States	15	555 1.3×	358 0.9×	133 0.9×	96 0.9×	135 1.6×	21	923
Martina Rahmeh Germany	13	476 1.1×	677 1.7×	197 1.3×	92 0.8×	140 1.6×	22	1.2k
Wei Wei Prior United States	8	644 1.5×	199 0.5×	147 1.0×	55 0.5×	91 1.0×	10	888
M V Blagosklonny United States	9	574 1.4×	426 1.1×	110 0.7×	190 1.7×	130 1.5×	11	989
Nicholas Davies United Kingdom	15	584 1.4×	298 0.8×	68 0.4×	191 1.7×	117 1.3×	25	1000
Gennaro Colella Italy	16	800 1.9×	439 1.1×	94 0.6×	70 0.6×	154 1.8×	29	1.1k
Michelle L. Kraus United States	7	466 1.1×	447 1.1×	124 0.8×	52 0.5×	129 1.5×	9	1.1k
Murray J. Towle United States	17	440 1.1×	509 1.3×	95 0.6×	162 1.5×	119 1.4×	24	1.1k
Randall Evans United States	13	609 1.5×	220 0.6×	59 0.4×	124 1.1×	132 1.5×	24	991
Karen M. Holdaway New Zealand	15	464 1.1×	279 0.7×	45 0.3×	61 0.6×	132 1.5×	19	776

Countries citing papers authored by H.H. Sedlacek

Since Specialization

Citations

This map shows the geographic impact of H.H. Sedlacek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H.H. Sedlacek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H.H. Sedlacek more than expected).

Fields of papers citing papers by H.H. Sedlacek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H.H. Sedlacek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H.H. Sedlacek. The network helps show where H.H. Sedlacek may publish in the future.

Co-authorship network of co-authors of H.H. Sedlacek

This figure shows the co-authorship network connecting the top 25 collaborators of H.H. Sedlacek. A scholar is included among the top collaborators of H.H. Sedlacek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H.H. Sedlacek. H.H. Sedlacek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Sedlacek, H.H.. (2001). Mechanisms of action of flavopiridol. Critical Reviews in Oncology/Hematology. 38(2). 139–170. 203 indexed citations

2.

Miller, Daniel W., Sabine Stahl, Michael Ernst, et al.. (1999). Elevated expression of endoglin, a component of the TGF-?-receptor complex, correlates with proliferation of tumor endothelial cells. International Journal of Cancer. 81(4). 568–572. 169 indexed citations

3.

Jäger, Walter, Peter Wolschann, Ernst Pittenauer, et al.. (1998). Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver. Life Sciences. 62(20). 1861–1873. 60 indexed citations

4.

Sedlacek, H.H., Jörg Czech, Ramachandra Naik, et al.. (1996). Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. International Journal of Oncology. 231 indexed citations

5.

Sedlacek, H.H., et al.. (1991). The Change in Research for the Therapy of Tumors. CHIMIA International Journal for Chemistry. 45(10). 311–311. 13 indexed citations

6.

Sedlacek, H.H.. (1989). The Chemotherapy of Malignant Diseases: Research Perspectives. Medical Entomology and Zoology. 1 indexed citations

7.

Schorlemmer, H. U., Klaus Bosslet, & H.H. Sedlacek. (1983). Ability of the immunomodulating dipeptide bestatin to activate cytotoxic mononuclear phagocytes.. PubMed. 43(9). 4148–53. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact